What are the best treatments for Henoch-Schönlein purpura?

TL;DR: Henoch-Schönlein purpura (HSP), now clinically known as IgA vasculitis, is primarily managed with supportive care, focusing on pain management and hydration. While most cases resolve spontaneously, severe manifestations involving the kidneys or gastrointestinal tract may require anti-inflammatory medications or immunosuppressive therapy tailored by a specialist.

What are the first-line treatments for Henoch-Schönlein purpura?

For most patients with Henoch-Schönlein purpura, treatment is supportive. Because the condition is self-limiting in the majority of children, clinicians prioritize rest, adequate fluid intake, and pain control. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen (Advil, Motrin) or naproxen (Aleve) are commonly used to manage joint pain (arthralgia) and abdominal discomfort, provided there is no evidence of active gastrointestinal bleeding or renal impairment.

When is medication required for IgA vasculitis?

In cases where Henoch-Schönlein purpura presents with severe gastrointestinal complications or significant renal involvement, more aggressive interventions are necessary. Corticosteroids, such as prednisone (Deltasone, Rayos), are frequently prescribed to reduce inflammation and manage symptoms. If kidney function is compromised, a multidisciplinary team may explore additional therapies, including:

• Immunosuppressants like azathioprine (Imuran) or cyclophosphamide (Cytoxan) for severe nephritis.


• Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to protect kidney function.


• Intravenous immunoglobulin (IVIG) in refractory or highly complex cases.

Which specialists should be on the care team?

Managing Henoch-Schönlein purpura often requires a coordinated, multidisciplinary approach to monitor for long-term complications. The core care team typically includes:

1. Pediatric Rheumatologist: To guide systemic anti-inflammatory management.


2. Pediatric Nephrologist: To monitor blood pressure and perform urinalysis, as approximately 20-50% of patients experience renal involvement.


3. Gastroenterologist: To monitor for rare but serious complications like intussusception.

How does treatment effectiveness vary?

Treatment effectiveness for Henoch-Schönlein purpura varies significantly based on the age of onset and the severity of organ involvement. While 106 members of the DiseaseMaps community have shared their experiences, clinical data shows that while most pediatric cases resolve within four weeks, adults with Henoch-Schönlein purpura often experience more severe renal outcomes, requiring longer-term monitoring.

Next steps

• Consult a pediatric rheumatologist or nephrologist for a personalized care plan.


• Maintain a log of symptoms, including blood pressure readings and urine test results.


• Join the DiseaseMaps community to connect with others who have navigated Henoch-Schönlein purpura.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice; always consult your healthcare team for diagnosis and treatment decisions.

References

• NIH Genetic and Rare Diseases Information Center (GARD): IgA Vasculitis (Henoch-Schönlein purpura).


• Orphanet: IgA Vasculitis (ORPHA:3335).


• American College of Rheumatology: Vasculitis in Children.


• UpToDate: IgA vasculitis (Henoch-Schönlein purpura): Management.